Suite Bonaire #7
We recently unveiled the G4X, ushering in a new era of spatial sequencing. The G4X combines two technologies into one singular platform: high-throughput in-situ spatial multiomics and next-generation sequencing, harnessing the power of the world’s most advanced benchtop sequencing platform. Stop by Suite Bonaire #7 to learn more about the new era of multiomic discovery.
Poster Presentation Wednesday, February 7
4:45pm ET at Palms I Ballroom
Suite Bonaire #7
Don’t miss the opportunity to play your favorite arcade games, score great prizes, and enjoy cocktails with the Singular team!
Palms Ballroom II and III
Explore the transformative impact the in-situ sequencing will have on the landscape of spatial biology during our technology showcase.
Grand Sierra Ballroom B
Kickstart your Thursday with a presentation highlighting the G4X Spatial Sequencer, it’s unprecedented multi-modal capabilities, and new data generated on the platform.
Generate powerful multiomic data from your samples with in situ sequencing and imaging on the G4X spatial sequencer.
Three recipients of the G4X Research Grant will receive spatial sequencing services for up to 40 10x10mm FFPE samples or equivalent use of imaging space and a travel grant to present the data at a conference.
Important Dates
Feb
5
Application Opens
Mar
20
Application Closes
Apr
5
Grants Awarded
We are now accepting submissions for the G4 Research Grant, giving researchers the opportunity to elevate their investigations with the world’s most powerful benchtop sequencer.
Important Dates
Feb
5
Application Opens
Mar
20
Application Closes
Apr
5
Grants Awarded
Single cell RNA sequencing application note developed in partnership with Fluent BioSciences
Cytogenomics application note developed in partnership with Phase Genomics
Proteomics application note developed in partnership with Olink
To apply, please fill out the application form below and upload project details using the template provided before March 20, 2024.
Drew founded Singular Genomics in 2016 serving as the CEO and Chairman. Drew is a serial entrepreneur and venture investor in the biotech industry and has been involved in the founding of several successful companies. Prior to Singular Genomics, Drew founded Truvian Sciences, a low volume blood testing technology aimed at making routine blood tests easier, less invasive, and more affordable. Drew was also involved in the founding of Aspen Neurosciences where he co-led the seed financing and helped assemble a world-class team to combat Parkinson’s Disease using a patient’s own stem cells. Drew was also a seed investor and held an operating role in Edico Genome which sold to Illumina in 2018.
Drew received an MBA from the Rady School of Management at the University of California, San Diego and a BA in Political Science and International Relations from the University of California, San Diego.
